Item 7.01 Regulation FD Disclosure.
Novanta Inc. (the "Company") will present at the CJS Securities 20th Annual "New
Ideas for the New Year" investor conference to be held on January 8, 2020. A
copy of the Company's conference presentation, which contains an overview of the
Company's business and the Company's 2020 financial outlook, is attached hereto
as Exhibit 99.1. The presentation is also available on the Company's website,
www.novanta.com, in the Investor Relations section.
The information contained in Exhibit 99.1 is furnished under this Item 7.01 and
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or incorporated by reference in any filing
thereunder or under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
Safe Harbor and Forward-Looking Information
Certain statements in the investor presentation attached hereto as Exhibit 99.1
are "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995 and are based on current expectations and
assumptions that are subject to risks and uncertainties. All statements
contained in this investor presentation that do not relate to matters of
historical fact should be considered forward-looking statements. These
forward-looking statements include, but are not limited to, statements regarding
2020 financial outlook; our operating model and value creation approach;
anticipated growth in certain products and market segments; and other statements
that are not historical facts.
These forward-looking statements are neither promises nor guarantees, but
involve risks and uncertainties that may cause actual results to differ
materially from those contained in the forward-looking statements. Our actual
results could differ materially from those anticipated in these forward-looking
statements for many reasons, including, but not limited to, the following:
economic and political conditions and the effects of these conditions on our
customers' businesses and level of business activity; our significant dependence
upon our customers' capital expenditures, which are subject to cyclical market
fluctuations; our dependence upon our ability to respond to fluctuations in
product demand; our ability to continually innovate and successfully
commercialize our innovations; failure to introduce new products in a timely
manner; customer order timing and other similar factors beyond our control;
disruptions or breaches in security of our information technology systems; our
failure to comply with data privacy regulations; changes in interest rates,
credit ratings or foreign currency exchange rates; risks associated with our
operations in foreign countries; risks associated with increased outsourcing of
components manufacturing; our exposure to increased tariffs, trade restrictions
or taxes on our products; our failure to comply with local import and export
regulations in the jurisdictions in which we operate; negative effects on global
economic conditions, financial markets and our business as a result of the
United Kingdom's impending withdrawal from the European Union and the actions of
the current U.S. government, including its policies on trade tariffs and
reactions from other countries to any new tariffs imposed by the U.S.;
violations of our intellectual property rights and our ability to protect our
intellectual property against infringement by third parties; risk of losing our
competitive advantage; our failure to successfully integrate recent and future
acquisitions into our businesses; our ability to attract and retain key
personnel; our restructuring and realignment activities and disruptions to our
operations as a result of consolidation of our operations; product defects or
problems integrating our products with other vendors' products; disruptions in
the supply of certain key components or other goods from our suppliers; our
failure to accurately forecast component and raw material requirements leading
to excess inventories or interruptions and delays in the delivery of our
products to customers; production difficulties and product delivery delays or
disruptions; our exposure to medical device regulation, which may impede or
hinder the approval or sale of our products and, in some cases, may ultimately
result in an inability to obtain approval of certain products or may result in
the recall or seizure of previously approved products; potential penalties for
violating foreign, U.S. federal, and state healthcare laws and regulations;
changes in governmental regulations affecting our businesses or products; our
failure to comply with environmental regulations; our failure to implement new
information technology systems and software successfully; our failure to realize
the full value of our intangible assets; our exposure to the credit risk of some
of our customers and in weakened markets; our reliance on third party
distribution channels; being subject to U.S. federal income taxation even though
we are a non-U.S. corporation; tax audits by tax authorities; changes in tax
laws, and fluctuations in our effective tax rates; any need for additional
capital to adequately respond to business challenges or opportunities and repay
or refinance our existing indebtedness, which may not be available on acceptable
terms or at all; our existing indebtedness limiting our ability to engage in
certain activities; volatility in the market price for our common shares;
provisions of our corporate documents that may delay or prevent a change in
control; and our failure to maintain appropriate internal controls in the
future.
Other important risk factors that could affect the outcome of the events set
forth in these statements and that could affect the Company's operating results
and financial condition are discussed in Item 1A of our Annual Report on Form
10-K for the fiscal year ended December 31, 2018, our subsequent filings with
the Securities and Exchange Commission ("SEC"), and in our future filings with
the SEC. Such statements are based on the Company's beliefs and assumptions and
on information currently available to the Company. The Company disclaims any
obligation to update any forward-looking statements as a result of developments
occurring after the date of this document except as required by law.
--------------------------------------------------------------------------------
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
99.1 Novanta Company Overview, January 2020
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
